RA
AMAG

Royce & Associates’s AMAG Pharmaceuticals AMAG Stock Holding History

Royce & Associates’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,412
Closed -$57K – 1217
2020
Q2 		$57K Sell
7,412
-9,524
-56% -$72.9K ﹤0.01% 1025
2020
Q1 		$105K Sell
16,936
-179,736
-91% -$1.58M ﹤0.01% 969
2019
Q4 		$2.39M Sell
196,672
-99,126
-34% -$1.08M 0.02% 666
2019
Q3 		$3.42M Sell
295,798
-263,509
-47% -$2.77M 0.03% 580
2019
Q2 		$5.59M Sell
559,307
-155,150
-22% -$1.67M 0.05% 465
2019
Q1 		$9.2M Buy
714,457
+47,553
+7% +$708K 0.08% 357
2018
Q4 		$10.1M Buy
666,904
+582,135
+687% +$11.1M 0.09% 314
2018
Q3 		$1.7M Buy
84,769
+83,890
+9,544% +$1.91M 0.01% 856
2018
Q2 		$17K Buy
879
+266
+43% +$5.88K ﹤0.01% 1157
2018
Q1 		$12K Sell
613
-246
-29% -$4.16K ﹤0.01% 1156
2017
Q4 		$11K Buy
859
+284
+49% +$4.28K ﹤0.01% 1172
2017
Q3 		$11K Buy
+575
New +$10.7K ﹤0.01% 1157
2015
Q4 		– Sell
-19,900
Closed -$791K – 1203
2015
Q3 		$791K Buy
+19,900
New +$1.24M ﹤0.01% 993

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royce & Associates's AMAG Position: Q3 2020 in Review

Royce & Associates sold out of AMAG Pharmaceuticals (AMAG) in Q3 2020, closing a stake of 7,412 shares — an estimated $57K sold.

Royce & Associates first reported a position in AMAG in Q3 2015 and held it in 13 quarters. The position peaked at $10.1M in Q4 2018. 113 funds tracked by Wall St. Rank hold AMAG as of Q3 2020.

  • Royce & Associates reported no remaining AMAG Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 7,412 AMAG Pharmaceuticals shares in Q3 2020, an estimated $57K.
  • Royce & Associates first reported a position in AMAG Pharmaceuticals in Q3 2015 and held it in 13 quarters.
  • Royce & Associates's AMAG Pharmaceuticals position peaked at $10.1M in Q4 2018.
  • 113 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.